Bibliografía científicaBibliografía científica

En esta sección encontrará una selección de las publicaciones científicas sobre los Trastornos del Movimiento para los 11 diferentes tipos establecidos por la International Parkinson & Movement Disorder Society. Se han seleccionado sólo aquellas publicaciones que presenten el término de búsqueda en el título (inglés).

Los artículos presentados incluyen aquellos publicados desde enero de 2010. El listado de publicaciones de actualizará mensualmente. Si lo desea, puede recibir una alerta de la actualización por correo electrónico. Para ello ha de registrarse.

Búsqueda
Enfermedad de Parkinson y Parkinsonismo Parkinson’s disease & Parkinsonism 2219 artículos Viendo del 1 al 40 de 2219 artículos
Pub MED

Verbal memory in drug-naive, newly diagnosed Parkinson's disease. The retrieval deficit hypothesis revisited.NUEVO

Brønnick K, Alves G, Aarsland D, Tysnes OB, Larsen JP.
Neuropsychology. 2011 Jan;25(1):114-24. doi: 10.1037/a0020857.
Pub MED

Urinary 8-OHdG elevations in a partial lesion rat model of Parkinson's disease correlate with behavioral symptoms and nigrostriatal dopaminergic depletion.NUEVO

Kikuchi Y, Yasuhara T, Agari T, Kondo A, Kuramoto S, Kameda M, Kadota T, Baba T, Tajiri N, Wang F, Tayra JT, Liang H, Miyoshi Y, Borlongan CV, Date I.
J Cell Physiol. 2011 May;226(5):1390-8. doi: 10.1002/jcp.22467.
Pub MED

Costs of illness and care in Parkinson's disease: an evaluation in six countries.NUEVO

von Campenhausen S, Winter Y, Rodrigues e Silva A, Sampaio C, Ruzicka E, Barone P, Poewe W, Guekht A, Mateus C, Pfeiffer KP, Berger K, Skoupa J, Bötzel K, Geiger-Gritsch S, Siebert U, Balzer-Geldsetzer M, Oertel WH, Dodel R, Reese JP.
Eur Neuropsychopharmacol. 2011 Feb;21(2):180-91. doi: 10.1016/j.euroneuro.2010.08.002.
Pub MED

The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders I: Parkinson's disease.NUEVO

Campos HC, da Rocha MD, Viegas FP, Nicastro PC, Fossaluzza PC, Fraga CA, Barreiro EJ, Viegas C Jr.
CNS Neurol Disord Drug Targets. 2011 Mar;10(2):239-50. Review.
Pub MED

Bupropion in the treatment of depression in Parkinson's disease.NUEVO

Załuska M, Dyduch A.
Int Psychogeriatr. 2011 Mar;23(2):325-7. doi: 10.1017/S1041610210001687.
Pub MED

Depression in Parkinson's disease: symptom improvement and residual symptoms after acute pharmacologic management.NUEVO

Dobkin RD, Menza M, Bienfait KL, Gara M, Marin H, Mark MH, Dicke A, Friedman J.
Am J Geriatr Psychiatry. 2011 Mar;19(3):222-9. doi: 10.1097/JGP.0b013e3181e448f7.
Pub MED

[Rehabilitation of Parkinson's patients with deep brain stimulation. Experiences of the Neurological Rehabilitation Center Godeshöhe].NUEVO

Allert N, Dohle C, Horn JW, Kelm S, Kirsch H, Nolte PN, Weirich W, Karbe H.
Nervenarzt. 2011 Apr;82(4):462-7. doi: 10.1007/s00115-010-3092-7. German.
Pub MED

Differences in odor identification among clinical subtypes of Parkinson's disease.NUEVO

Iijima M, Kobayakawa T, Saito S, Osawa M, Tsutsumi Y, Hashimoto S, Uchiyama S.
Eur J Neurol. 2011 Mar;18(3):425-9. doi: 10.1111/j.1468-1331.2010.03167.x.
Pub MED

Effect of robotic locomotor training in an individual with Parkinson's disease: a case report.NUEVO

Ustinova K, Chernikova L, Bilimenko A, Telenkov A, Epstein N.
Disabil Rehabil Assist Technol. 2011;6(1):77-85. doi: 10.3109/17483107.2010.507856.
Pub MED

Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease.NUEVO

Frau L, Borsini F, Wardas J, Khairnar AS, Schintu N, Morelli M.
Synapse. 2011 Mar;65(3):181-8. doi: 10.1002/syn.20833.
Pub MED

New LRRK2 variants identified in Parkinson's disease.NUEVO

Tan EK, Schapira AH.
Eur J Neurol. 2011 Mar;18(3):369-70. doi: 10.1111/j.1468-1331.2010.03163.x. No abstract available.
Pub MED

Confirmation of LRRK2 S1647T variant as a risk factor for Parkinson's disease in southern China.NUEVO

Zheng Y, Liu Y, Wu Q, Hong H, Zhou H, Chen J, Wang H, Xian W, Li J, Liu Z, Pei Z, Chen L.
Eur J Neurol. 2011 Mar;18(3):538-40. doi: 10.1111/j.1468-1331.2010.03164.x.
Pub MED

Cardiovascular dysautonomia in de novo Parkinson's disease without orthostatic hypotension.NUEVO

Oka H, Toyoda C, Yogo M, Mochio S.
Eur J Neurol. 2011 Feb;18(2):286-92. doi: 10.1111/j.1468-1331.2010.03135.x.
Pub MED

Heart trouble comes early in Parkinson's disease before blood pressure falls.NUEVO

Haensch CA.
Eur J Neurol. 2011 Feb;18(2):201-2. doi: 10.1111/j.1468-1331.2010.03136.x. No abstract available.
Pub MED

Morphologic changes and functional retinal impairment in patients with Parkinson disease without visual loss.NUEVO

Moschos MM, Tagaris G, Markopoulos I, Margetis I, Tsapakis S, Kanakis M, Koutsandrea C.
Eur J Ophthalmol. 2011 Jan-Feb;21(1):24-9.
Pub MED

Rapid assessment of postural instability in Parkinson's disease (RAPID): a pilot study.NUEVO

Chong RK, Morgan J, Mehta SH, Pawlikowska I, Hall P, Ellis AV, Ibanez-Wong AD, Miller GM, Baugh K, Sethi K.
Eur J Neurol. 2011 Feb;18(2):260-5. doi: 10.1111/j.1468-1331.2010.03115.x.
Pub MED

Parkinson-related genetics in patients treated with deep brain stimulation.NUEVO

Johansen KK, Jørgensen JV, White LR, Farrer MJ, Aasly JO.
Acta Neurol Scand. 2011 Mar;123(3):201-6. doi: 10.1111/j.1600-0404.2010.01387.x.
Pub MED

Recurrent falls and mortality in Parkinson's disease: a prospective two-year follow-up study.NUEVO

Matinolli M, Korpelainen JT, Sotaniemi KA, Myllylä VV, Korpelainen R.
Acta Neurol Scand. 2011 Mar;123(3):193-200. doi: 10.1111/j.1600-0404.2010.01386.x.
Pub MED

Dietary intake of antioxidant vitamins and risk of Parkinson's disease: a case-control study in Japan.NUEVO

Miyake Y, Fukushima W, Tanaka K, Sasaki S, Kiyohara C, Tsuboi Y, Yamada T, Oeda T, Miki T, Kawamura N, Sakae N, Fukuyama H, Hirota Y, Nagai M; Fukuoka Kinki Parkinson's Disease Study Group..
Eur J Neurol. 2011 Jan;18(1):106-13. doi: 10.1111/j.1468-1331.2010.03088.x.
Pub MED

Evaluation of fatigue in Parkinson's disease using the Brazilian version of Parkinson's Fatigue Scale.NUEVO

Kummer A, Scalzo P, Cardoso F, Teixeira AL.
Acta Neurol Scand. 2011 Feb;123(2):130-6. doi: 10.1111/j.1600-0404.2010.01364.x.
Pub MED

Endometrial stem cell transplantation restores dopamine production in a Parkinson's disease model.NUEVO

Wolff EF, Gao XB, Yao KV, Andrews ZB, Du H, Elsworth JD, Taylor HS.
J Cell Mol Med. 2011 Apr;15(4):747-55. doi: 10.1111/j.1582-4934.2010.01068.x.
Pub MED

Case report of electroconvulsive therapy in a patient with Parkinson disease concomitant with deep brain stimulation.NUEVO

Nasr S, Murillo A, Katariwala N, Mothkur V, Wendt B.
J ECT. 2011 Mar;27(1):89-90. doi: 10.1097/YCT.0b013e3181da843c.
Pub MED

Exercise and Parkinson's: benefits for cognition and quality of life.NUEVO

Cruise KE, Bucks RS, Loftus AM, Newton RU, Pegoraro R, Thomas MG.
Acta Neurol Scand. 2011 Jan;123(1):13-9. doi: 10.1111/j.1600-0404.2010.01338.x.
Pub MED

Activities of daily living and quality of life in persons with newly diagnosed Parkinson's disease according to subtype of disease, and in comparison to healthy controls.NUEVO

Hariz GM, Forsgren L.
Acta Neurol Scand. 2011 Jan;123(1):20-7. doi: 10.1111/j.1600-0404.2010.01344.x.
Pub MED

A neurocomputational model of dopamine and prefrontal-striatal interactions during multicue category learning by Parkinson patients.NUEVO

Moustafa AA, Gluck MA.
J Cogn Neurosci. 2011 Jan;23(1):151-67. doi: 10.1162/jocn.2010.21420.
Pub MED

Successful intra-arterial chemotherapy for extramammary Paget's disease of the axilla in a patient with Parkinson's disease.NUEVO

Damascelli B, Ticha V.
Cardiovasc Intervent Radiol. 2011 Feb;34 Suppl 2:S167-70. doi: 10.1007/s00270-009-9786-1.
Pub MED

A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease.NUEVO

Krüger R, Sharma M, Riess O, Gasser T, Van Broeckhoven C, Theuns J, Aasly J, Annesi G, Bentivoglio AR, Brice A, Djarmati A, Elbaz A, Farrer M, Ferrarese C, Gibson JM, Hadjigeorgiou GM, Hattori N, Ioannidis JP, Jasinska-Myga B, Klein C, Lambert JC, Lesage S, et al.
Neurobiol Aging. 2011 Mar;32(3):548.e9-18. doi: 10.1016/j.neurobiolaging.2009.11.021.
Pub MED

Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease.NUEVO

Zhang W, Phillips K, Wielgus AR, Liu J, Albertini A, Zucca FA, Faust R, Qian SY, Miller DS, Chignell CF, Wilson B, Jackson-Lewis V, Przedborski S, Joset D, Loike J, Hong JS, Sulzer D, Zecca L.
Neurotox Res. 2011 Jan;19(1):63-72. doi: 10.1007/s12640-009-9140-z.
Pub MED

Different MAPT haplotypes are associated with Parkinson's disease and progressive supranuclear palsy.NUEVO

Ezquerra M, Pastor P, Gaig C, Vidal-Taboada JM, Cruchaga C, Muñoz E, Martí MJ, Valldeoriola F, Aguilar M, Calopa M, Hernandez-Vara J, Tolosa E.
Neurobiol Aging. 2011 Mar;32(3):547.e11-6. doi: 10.1016/j.neurobiolaging.2009.09.011.
Pub MED

Treatment of idiopathic Parkinson's disease with traditional chinese herbal medicine: a randomized placebo-controlled pilot clinical study.NUEVO

Kum WF, Durairajan SS, Bian ZX, Man SC, Lam YC, Xie LX, Lu JH, Wang Y, Huang XZ, Li M.
Evid Based Complement Alternat Med. 2011;2011:724353. doi: 10.1093/ecam/nep116.
Pub MED

Voxel-based analysis of diffusion tensor indices in the brain in patients with Parkinson's disease.NUEVO

Zhang K, Yu C, Zhang Y, Wu X, Zhu C, Chan P, Li K.
Eur J Radiol. 2011 Feb;77(2):269-73. doi: 10.1016/j.ejrad.2009.07.032.
Pub MED

Overreaction to noncompaction in a patient with ankylosing spondylitis, Parkinson disease, migraine and myopathy.NUEVO

Stöllberger C, Stix A, Finsterer J.
Int J Cardiol. 2011 Jul 1;150(1):e11-4. doi: 10.1016/j.ijcard.2009.06.030.
Pub MED

Sudden bilateral corneal oedema in a patient with Parkinson's disease.NUEVO

Park CY, Chuck RS.
Acta Ophthalmol. 2011 Mar;89(2):198-9. doi: 10.1111/j.1755-3768.2009.01561.x. No abstract available.
Pub MED

GSK3β polymorphisms, MAPT H1 haplotype and Parkinson's disease in a Greek cohort.NUEVO

Kalinderi K, Fidani L, Katsarou Z, Clarimón J, Bostantjopoulou S, Kotsis A.
Neurobiol Aging. 2011 Mar;32(3):546.e1-5. doi: 10.1016/j.neurobiolaging.2009.05.007.
Pub MED

Predictors of cognitive and psychosocial outcome after STN DBS in Parkinson's Disease.NUEVO

Smeding HM, Speelman JD, Huizenga HM, Schuurman PR, Schmand B.
J Neurol Neurosurg Psychiatry. 2011 Jul;82(7):754-60. doi: 10.1136/jnnp.2007.140012.
Pub MED

Transcription factor PITX3 gene in Parkinson's disease.NUEVO

Le W, Nguyen D, Lin XW, Rawal P, Huang M, Ding Y, Xie W, Deng H, Jankovic J.
Neurobiol Aging. 2011 Apr;32(4):750-3. doi: 10.1016/j.neurobiolaging.2009.03.015.
Pub MED

New evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease.NUEVO

Shan S, Hong-Min T, Yi F, Jun-Peng G, Yue F, Yan-Hong T, Yun-Ke Y, Wen-Wei L, Xiang-Yu W, Jun M, Guo-Hua W, Ya-Ling H, Hua-Wei L, Ding-Fang C.
Neurobiol Aging. 2011 Mar;32(3):443-58. doi: 10.1016/j.neurobiolaging.2009.03.004.
Pub MED

Association of transcription factor polymorphisms PITX3 and EN1 with Parkinson's disease.NUEVO

Haubenberger D, Reinthaler E, Mueller JC, Pirker W, Katzenschlager R, Froehlich R, Bruecke T, Daniel G, Auff E, Zimprich A.
Neurobiol Aging. 2011 Feb;32(2):302-7. doi: 10.1016/j.neurobiolaging.2009.02.015.
Pub MED

GIGYF2 has no major role in Parkinson genetic etiology in a Belgian population.NUEVO

Meeus B, Nuytemans K, Crosiers D, Engelborghs S, Pals P, Pickut B, Peeters K, Mattheijssens M, Corsmit E, Cras P, De Deyn PP, Theuns J, Van Broeckhoven C.
Neurobiol Aging. 2011 Feb;32(2):308-12. doi: 10.1016/j.neurobiolaging.2009.02.016.
Pub MED

Effects of aging, Parkinson's disease, and dopaminergic medication on response selection and control.NUEVO

Willemssen R, Falkenstein M, Schwarz M, Müller T, Beste C.
Neurobiol Aging. 2011 Feb;32(2):327-35. doi: 10.1016/j.neurobiolaging.2009.02.002.
Viendo del 1 al 40 de 2219 artículos
Con el aval de:

Sociedad Española de Neurología

Sociedad Española
de Neurología
En colaboración con:

Zambon

Haga click en el logo para acceder
a información acerca de Zambon
NeuroAcademy
Utilizamos cookies propias y de terceros para identificar la sesión del usuario y mejorar nuestros servicios mediante el análisis de sus hábitos de navegación. Si continúa navegando por el sitio web manifiesta consentir su instalación y uso conforme lo anterior. Puede cambiar la configuración y obtener más información aquí.